Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Days Abstinent
Timeframe: 12 weeks
Percentage of Heavy Drinking Days
Timeframe: 12 weeks
Alcohol Consumption (Percentage of Negative Urines)
Timeframe: 12 weeks